Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates through two segments, Ypsomed Delivery Systems and Ypsomed Diabetes Care. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
Stock data | 2023 | Change |
---|---|---|
Price | $454.44 | N/A |
Market Cap | $6.10B | N/A |
Shares Outstanding | 13.42M | 6.12% |
Employees | 2.20K | N/A |
Shareholder Equity | 562.33M | 43.25% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | 118.96 | N/A |
P/S Ratio | 10.39 | N/A |
P/B Ratio | 10.84 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | 0.1076 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $587.18M | N/A |
Earnings | $60.52M | N/A |
EPS | 3.82 | N/A |
Earnings Yield | 0.0084 | N/A |
Gross Margin | 0.2826 | N/A |
Operating Margin | 0.1218 | N/A |
Net income margin | 0.1031 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $1.02B | N/A |
Total Debt | $185.32M | N/A |
Cash on Hand | $29.77M | N/A |
Debt to Equity | 0.6288 | -42.61% |
Cash to Debt | 0.1607 | 151.77% |
Current Ratio | 0.8044 | -1.38% |